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component of intercellular communication (Geddings and Mackman,
2014; Shantsila et al., 2014). They may be involved in more complex
regulatory pathways due to their capacity to deliver multiple molecules
in the same lipid envelope and to speciﬁcally target particular types of
cells using their surface receptors. Patients with hypertension and sys-Keywords:
Heart failure
Heart failure with preserved ejection fraction
Endothelial progenitor cells
MicroparticlesHeart failure (HF) with preserved ejection fraction (HFpEF) has
emerged as a major problem of modern cardiology. In contrast to HF
with systolic impairment advances in management of HFpEF have
been humble and there is lack of proven effective treatment to improve
longevity and reduce disability in such patients. Futility of the medica-
tions established in systolic HF to help subjects with HFpEF reﬂects dif-
ference in the pathophysiological mechanisms of the two forms of HF.
Good understanding of these mechanisms is essential for discovery of
new treatments in the future.
The numbers of endothelial progenitor cells (EPCs) are upregulated
in systolic HF and their numbers correlate with levels of various cyto-
kines, such as tumor necrosis factor-alpha (Valgimigli et al., 2004).
However EPC counts vary depending on the stage of HF with relatively
higher levels seen in mild or well-controlled disease but the numbers
decrease progressively in advanced HF stages (Valgimigli et al., 2004).
Hypertension is a major cause of HFpEF as opposed to ischemia in
systolic HF. Diastolic dysfunction and abnormal cardiac stiffness are rec-
ognized factors predisposing to the development of HFpEF in patients
with high blood pressure (Komajda and Lam, 2014). Hypertension is
related to impairment of EPC migratory capacity in vitro. This may be
partly explained by upregulation of angiotensin II, a molecule shown
to reduce telomerase activity in EPCs and to accelerate their senescence
(Imanishi et al., 2005).om.2016.01.018.
. This is an open access article undertolic HF have abnormal levels of different types of blood microparticles
but data on microparticles in HFpEF are scarce.
EPCs are diverse and they embrace cells of different progeny
(Shantsila et al., 2007). Two types of EPCs appear to be of particular rel-
evance. ‘Late’ EPCs are extremely scarce in circulation and they most
likely represent cells resident within the endothelium. When appropri-
ately stimulated they have immense proliferative capacity and can give
origin to endothelia cells per se. However, their assessment is limited
but the requirement for long-term in vitro culture experiments. The
other major types of EPCs are so called ‘early’ EPCs, which produce nu-
merous endothelial like cells within few days of in vitro culture. They
have been shown to be predominantly of monocytic origin and they
contribute to angiogenesis by releasing appropriate cytokines,
chemokines, growth factors, etc., thus orchestrating mobilization of
other cell types and modulating activity of the tissue resident cells.
Given the monocytic origin of these cells they can be assessed by ﬂow
cytometry from fresh blood samples. This opportunity has been utilized
Berezin et al. in their study published in this issue of EBioMedicine
(Berezin et al., 2016).
Berezin et al. have demonstrated signiﬁcant differences in the pat-
tern of circulating EPCs and endothelial microparticles in patients with
HF with reduced or preserved ejection fraction (Berezin et al., 2016).
The study provides several interesting observations. Among the differ-
ent EPC phenotypes assessed, only CD14+ cells (i.e., cells of monocytic
origin) were independently associated with HFpEF. This accords with
extensive and ongoing cardiac remodeling in patients with HFpEF.
However detailed relationship between the tested parameters and
measures of cardiac remodeling and outcomes were beyond the scope
of the present study and need to be established in the future in prospec-
tive trials. Such information is essential to establish whether the tested
pathways could produce clinically relevant therapeutic targets.
Of interest, in the study by Berezin et al. HFpEFwas related to upreg-
ulation of monocytes with angiogenic phenotypy rather than cells with
‘classical’ CD34+CD309+ EPC phenotype (Berezin et al., 2016; Cesari
et al., 2014). This ﬁts well in the progressively better-understood role
of a speciﬁc monocyte population (i.e., ‘intermediate’ or Mon2 subset)the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ing HF. In fact, this subset has been shown to have highest of all mono-
cyte expression of CD309, Tie-2 and a range of other receptors involved
in angiogenesis and tissue remodeling (Shantsila et al., 2011). The re-
sults obtained by Berezin et al. also correspond to recent observations
that non-monocytic circulating EPCs can in fact be downregulated in
HFpEF compared to controls without HF thus highlighting the impor-
tance of careful characterization of speciﬁc phenotype of cells assessed
under generic term of EPCs (Chiang et al., 2013).
Berezin et al. show that changes in proportions of certain types of
microparticles (CD31+ could be shed from both endothelial cells and
platelets) and angiogenic monocytes are linked to the type of HF
(Berezin et al., 2016). It is possible that these changes are secondary to
the degree of the background ischemia or shifts in cardiac and vascular
hemodynamics associated with particular HF form (for example, in-
creased endothelial shear stress in hypertension). However it can also
reﬂect poorly understood aspects of endothelial dysfunction. Indeed,
while the role of endothelial dysfunction is well-established magnitude
and nature of endothelial changes in HFpEF are less clear.
Extensive experimental work is also warranted to identify and de-
scribe the whole length of the pathophysiological pathways implicated
in the processesmediated by angiogenic monocytes andmicroparticles.
This will help to determine the key components of the pathways, which
will help to modulate them in the desired direction.
The studydoes not answer thequestion ofwhether the observedup-
regulation of biomarkers is involved in the development of HFpEF or
they reﬂect a mechanism aiming to contrabalance the pathogenic fac-
tors or to promote adaptation of the cardiovascular system to hemody-
namic changes. These questions will need to be answered in the future.
Overall the study byBerezin and colleagues provides new insight in pro-
cesses differentiatingHFpEF and systolic HF and it leads to a string of in-
teresting hypotheses to be tested in the future.Conﬂicts of interest
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